Article ID Journal Published Year Pages File Type
7390607 Value in Health Regional Issues 2014 7 Pages PDF
Abstract
Despite linezolid's higher drug acquisition cost, its superior clinical efficacy renders it a likely cost-effective alternative for the treatment of methicillin-resistant Staphylococcus aureus-confirmed nosocomial pneumonia as compared with branded vancomycin from the payer perspectives of Beijing, Guangzhou, Nanjing, and Xi'an.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China
Authors
, , , , , , , , , , ,